Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)
about
Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and futureLixisenatide in type 2 diabetes: latest evidence and clinical usefulnessAdvances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert ForumAdverse Effects of GLP-1 Receptor AgonistsBasal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision makingLixisenatide as add-on therapy to basal insulinCan medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery?Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetesCardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-AnalysisUpdate on the treatment of type 2 diabetes mellitusTreatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonistsEfficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review.Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Lixisenatide reduces glycaemic variability in insulin-treated patients with type 2 diabetes.Challenges associated with insulin therapy progression among patients with type 2 diabetes: Latin American MOSAIc study baseline dataLixisenatide Improves Glycemic Control in Asian Type 2 Diabetic Patients Inadequately Controlled With Oral Antidiabetic Drugs: An Individual Patient Data Meta-AnalysisSwitch to Combined GLP1 Receptor Agonist Lixisenatide with Basal Insulin Glargine in Poorly Controlled T2DM Patients with Premixed Insulin Therapy: A Clinical Observation and Pilot Study in Nine Patients.Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes--a study in both people with type 2 diabetes and healthy subjects.The clinical development program of lixisenatide: a once-daily glucagon-like Peptide-1 receptor agonist.Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-SInjectable Coformulations in DiabetologyNovel Agents for the Treatment of Type 2 Diabetes.Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-AnalysisTherapeutic Options for the Management of Postprandial Glucose in Patients With Type 2 Diabetes on Basal Insulin.Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial)Evaluation of the efficacy and safety of lixisenatide add-on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal trialsHow much is too much? Outcomes in patients using high-dose insulin glargine.Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects.Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone.Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies.Combination therapy of glucagon-like peptide-1 receptor agonists and insulin for patients who developed diabetes after partial pancreatectomyInsulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetesEfficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X).Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III studyEfficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial.Effect of the glucagon-like peptide-1 receptor agonist lixisenatide on postprandial hepatic glucose metabolism in the conscious dogPathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies.Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US.A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease.Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.
P2860
Q26752699-56A5712D-5B19-4F11-A3BB-2591A0031EEEQ26771823-FFFF9AE8-8EDC-4547-96D9-AF33E6E27B33Q26784022-D9F390DE-129E-4B99-96ED-8152A963E538Q26801346-F39EA43D-73AB-4708-9589-C4AE6F757980Q26992979-44D7D2AC-80D2-4E98-B843-BBB703351299Q27007547-5DF0FFE1-1648-4804-8FB2-7513CEA83C8DQ27015789-0605D444-5879-4B0A-B494-54B23A4EB393Q27025423-5A34E754-CDF9-491D-8666-3983CC79DDB2Q28071764-5D9C8A43-4556-4C2B-A5C0-1D18AF32C097Q28073342-22957EB3-59D9-4ADB-88CA-3C2F5828636FQ28077026-B26D326C-FAE6-4A47-9426-C3212483860CQ30240808-5697D511-7AED-4149-A6B9-AABB9FAAB528Q30249371-BB8A655C-44CB-4DD1-801B-61B16279B5A0Q30253045-3FC7455D-E88A-452D-BF98-FAE8E60CEB4DQ31117218-7326B1F2-934E-45CD-92C8-EEC9898010D5Q31140045-18755B89-427E-492A-992B-FB7746B62E1EQ33732588-B1C67603-EDE3-4CE2-B1B5-A178A255E8C3Q34543003-31A74AE0-382C-446E-9773-1218CD368307Q34726309-A5124015-BEB0-4A86-B101-2010234C857DQ35192193-D5362D4E-A875-48F2-9B48-4B5B984378A4Q35772586-66F1284D-9164-4760-91AA-496CABC7D94CQ35910421-279A146B-8F1D-4BA0-927E-993871F46F77Q36011993-82D81481-0016-43A2-AFC1-62631BF04E2AQ36169413-27054C86-D5AD-4635-9B1A-70740D059CB7Q36220895-005B0340-F466-4B17-9793-8D74ABDCB4ADQ36303980-503FA7AF-9853-4A14-84FD-A9F6BEAB0488Q36536807-03753C24-D512-4E50-9C99-33D17D191C87Q36554216-983555CE-16AA-4F1C-9A2D-D81145B7B881Q36712701-3F2A41F9-0608-46F2-861F-F5E1235614B4Q36803151-07C838C1-0255-47D8-9D7E-7426C89750C1Q36843912-5517A740-3108-409B-8E70-DCC92F5ACDE4Q36971833-5454866C-3987-4522-819D-082D5A11BF1DQ37193446-945EAB7A-CA49-4512-B8CA-95460A04E903Q37295997-89F7C33B-4F82-455D-9495-3203CF821BCEQ37320537-F6DC47EA-6EFC-4FFA-B977-6EB8F09A23A4Q37439806-4C90B70E-2911-40A0-A6F1-DA3DD13E5BD1Q37446672-876C6A01-BA49-468F-887E-3B5AF45AD10EQ37538487-710BBDC2-E5C2-4057-AB1E-3AD87A197300Q37568754-43EC711D-FD80-495A-8706-D573BB61B101Q37598881-DFD96D27-5815-495E-BE17-8952BC31A412
P2860
Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 April 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Adding once-daily lixisenatide ...... trolled comparison (GetGoal-L)
@en
Adding once-daily lixisenatide ...... rolled comparison (GetGoal-L).
@nl
type
label
Adding once-daily lixisenatide ...... trolled comparison (GetGoal-L)
@en
Adding once-daily lixisenatide ...... rolled comparison (GetGoal-L).
@nl
prefLabel
Adding once-daily lixisenatide ...... trolled comparison (GetGoal-L)
@en
Adding once-daily lixisenatide ...... rolled comparison (GetGoal-L).
@nl
P2093
P2860
P921
P356
P1433
P1476
Adding once-daily lixisenatide ...... trolled comparison (GetGoal-L)
@en
P2093
Elisabeth Niemoeller
Matthew C Riddle
Patrick Miossec
Philip Home
Ronnie Aronson
P2860
P304
P356
10.2337/DC12-2454
P407
P577
2013-04-29T00:00:00Z